{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:26:21Z","timestamp":1792409181140,"version":"4.4.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Buprenorphine is a first-line medication for opioid use disorder, yet many individuals face barriers to filling buprenorphine prescriptions. Telemedicine patients may have prescriptions questioned and rejected more frequently due to being perceived as a diversion risk due to their prescriber\u2019s physical distance from the pharmacy.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate pharmacy challenges in filling buprenorphine prescriptions among adults receiving telemedicine treatment for opioid use disorder overall and by rural and nonrural residence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cross-sectional study analyzed a web-based survey conducted from August to September 2024. Adult patients receiving treatment from a telemedicine practice providing low-barrier treatment for opioid use disorder in 5 US states were included. Participants were identified through electronic health records; inclusion criteria were diagnosis of opioid use disorder, enrollment in telemedicine treatment with a valid zip code, and completion of a new evaluation visit and follow-up appointment.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Rural and nonrural residence determined by patient zip codes mapped to Rural-Urban Commuting Area codes.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Self-reported frequency of buprenorphine fill problems in the past year, types of fill problems, and days without buprenorphine due to pharmacy-related challenges.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 601 patients participated, with 300 (49.9%) residing in nonrural areas, 363 (60.4%) identifying as women, and a mean (SD) age of 41.44 (8.60) years. Nearly one-third of patients (192 [31.9%]) had to go without buprenorphine due to a pharmacy-related barrier in the past 12 months, and more than one-quarter (165 [27.5%]) reported having problems filling their buprenorphine prescription. There was no statistically significant difference in the experience of buprenorphine fill problems between rural and nonrural respondents. The most common problems were that buprenorphine was unavailable and needed ordering (90 of 165 [54.5%]), insurance coverage-related barriers (37 [22.4%]), and pharmacy hesitancy in filling a telemedicine prescription (32 [19.4%]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study of patients receiving telemedicine treatment for opioid use disorder, challenges filling buprenorphine prescriptions were prevalent and led to concerning periods when patients were untreated and at an increased risk of returning to nonprescribed opioid use. There is a critical need for interventions to ensure sufficient access to buprenorphine, including implementing buprenorphine stocking requirements and medication delivery services through collaborating pharmacies.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.27418","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T15:31:17Z","timestamp":1755531077000},"page":"e2527418","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacy Barriers to Receiving Buprenorphine Among Patients Undergoing Telemedicine Addiction Treatment"],"prefix":"10.1001","volume":"8","author":[{"given":"Lauren E.","family":"Hendy","sequence":"first","affiliation":[{"name":"Workit Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Olguin","sequence":"additional","affiliation":[{"name":"Workit Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Barrett","sequence":"additional","affiliation":[{"name":"Workit Health, Albuquerque, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Jimes","sequence":"additional","affiliation":[{"name":"Workit Health, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Justin","family":"Coffey","sequence":"additional","affiliation":[{"name":"Workit Health, Ann Arbor, Michigan"},{"name":"Department of Psychiatry, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene C.","family":"Lira","sequence":"additional","affiliation":[{"name":"Workit Health, Ann Arbor, Michigan"},{"name":"Health Policy, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"5","key":"zoi250772r3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/jamapsychiatry.2023.0310","article-title":"Association of receipt of opioid use disorder-related telehealth services and medications for opioid use disorder with fatal drug overdoses among Medicare beneficiaries before and during the COVID-19 pandemic.","volume":"80","author":"Jones","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"zoi250772r4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder.","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"key":"zoi250772r5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jsat.2014.12.011","article-title":"Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.","volume":"52","author":"Bentzley","year":"2015","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"zoi250772r6","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxad013","article-title":"Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United States.","volume":"1","author":"Krawczyk","year":"2023","journal-title":"Health Aff Sch"},{"issue":"12","key":"zoi250772r7","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/jamapsychiatry.2024.3076","article-title":"Addressing the escalating problems that patients encounter when filling buprenorphine prescriptions.","volume":"81","author":"Winstanley","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"zoi250772r8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1176\/appi.ps.202100191","article-title":"Telehealth adoption by mental health and substance use disorder treatment facilities in the COVID-19 pandemic.","volume":"73","author":"Cantor","year":"2022","journal-title":"Psychiatr Serv"},{"issue":"1","key":"zoi250772r9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.amepre.2024.09.013","article-title":"Utilization of buprenorphine for opioid use disorder after the practitioner waiver removal.","volume":"68","author":"Ali","year":"2025","journal-title":"Am J Prev Med"},{"issue":"4","key":"zoi250772r10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.japh.2023.04.029","article-title":"Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility.","volume":"63","author":"Ostrach","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"key":"zoi250772r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"zoi250772r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16089","article-title":"Pharmacy availability of buprenorphine for opioid use disorder treatment in the US.","volume":"6","author":"Weiner","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi250772r14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/29767342231215178","article-title":"Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: results from a national sample.","volume":"45","author":"Light","year":"2024","journal-title":"Subst Use Addctn J"},{"issue":"1","key":"zoi250772r15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: A national survey of community-based pharmacists.","volume":"63","author":"Hill","year":"2023","journal-title":"J Am Pharm Assoc (2003)"},{"key":"zoi250772r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2022.100204","article-title":"Factors in rural community buprenorphine dispensing.","volume":"9","author":"Major","year":"2022","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"2","key":"zoi250772r17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.japh.2021.10.002","article-title":"Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.","volume":"62","author":"Ostrach","year":"2022","journal-title":"J Am Pharm Assoc (2003)"},{"key":"zoi250772r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u2018Red flags\u2019 and \u2018red tape\u2019: telehealth and pharmacy-level barriers to buprenorphine in the United States.","volume":"105","author":"Textor","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"2S","key":"zoi250772r19","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia.","volume":"57","author":"Thornton","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"zoi250772r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2022.100091","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use.","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"zoi250772r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the US opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky.","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"12","key":"zoi250772r23","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1377\/hlthaff.2019.00910","article-title":"What is rural? challenges and implications of definitions that inadequately encompass rural people and places.","volume":"38","author":"Bennett","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"zoi250772r24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/ADM.0000000000001244","article-title":"A brief online training to address pharmacists\u2019 willingness to dispense buprenorphine.","volume":"18","author":"Carpenter","year":"2024","journal-title":"J Addict Med"},{"issue":"11","key":"zoi250772r27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.18553\/jmcp.2016.22.11.1247","article-title":"Examination of the link between medication adherence and use of mail-order pharmacies in chronic disease states.","volume":"22","author":"Fernandez","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"zoi250772r28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12954-024-01118-3","article-title":"Analysis of different populations accessing online overdose response training and harm reduction supplies (ADORES).","volume":"21","author":"Pacheco","year":"2024","journal-title":"Harm Reduct J"},{"issue":"1","key":"zoi250772r29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13722-025-00545-2","article-title":"Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder.","volume":"20","author":"C Lira","year":"2025","journal-title":"Addict Sci Clin Pract"},{"key":"zoi250772r25","doi-asserted-by":"crossref","DOI":"10.52713\/PhARM-OUD","volume-title":"The Pharmacy Access to Resources and Medication for Opioid Use Disorder (PhARM-OUD) Guideline","author":"Varisco","year":"2024"},{"key":"zoi250772r1","unstructured":"Substance Abuse and Mental Health Services Administration. 2023 NSDUH annual report. Accessed July 16, 2025. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"zoi250772r2","doi-asserted-by":"crossref","unstructured":"Garnett? MF, Mini\u00f1o? AM. Drug overdose deaths in the United States, 2003-2023. NCHS Data Brief, No. 522. December 2024. Accessed July 16, 2025. https:\/\/stacks.cdc.gov\/view\/cdc\/170565","DOI":"10.15620\/cdc\/170565"},{"key":"zoi250772r13","unstructured":"Milgram? A, Levine? R, Delphin-Rittmon? M. Joint DEA and DHHS letter to distributors on MOUD access. Accessed February 19, 2025. https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/Dear_Registrant_MOUD.pdf"},{"key":"zoi250772r20","unstructured":"US Department of Agriculture Economic Research Service. Rural-Urban Commuting Area Codes\u2014documentation. Accessed December 9, 2024. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-commuting-area-codes\/documentation\/"},{"key":"zoi250772r26","unstructured":"Gliadkovskaya? A. Walmart implements new policy, denies many telehealth scripts. Fierce Healthcare. August 9, 2022. Accessed February 24, 2025. https:\/\/www.fiercehealthcare.com\/digital-health\/new-policy-walmart-denies-telehealth-prescriptions-without-person-visit"},{"key":"zoi250772r30","unstructured":"New Mexico Overdose Prevention and Pain Management Advisory Council. OPPM buprenorphine access recommendation. May 8, 2024. Accessed February 6, 2025. https:\/\/www.nmhealth.org\/publication\/view\/meeting\/8939\/"},{"key":"zoi250772r31","unstructured":"San Francisco Board of Supervisors. Requiring retail pharmacies to stock opioid antagonists and buprenorphine (ordinance No. 206-24). Accessed February 6, 2025. https:\/\/sfbos.org\/sites\/default\/files\/o0206-24.pdf"},{"key":"zoi250772r32","unstructured":"BUPE for Recovery Act, HR 9886, 118th Cong (2024). Accessed July 16, 2025. https:\/\/www.congress.gov\/bill\/118th-congress\/house-bill\/9886\/text"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837665\/hendy_2025_oi_250772_1754671704.91788.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T15:31:19Z","timestamp":1755531079000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27418","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]}}}